Abrilumab

Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) [1].

Product Specifications

CAS Number

1342290-43-0

UNSPSC

12352203

Target

Integrin

Type

Inhibitory Antibodies

Related Pathways

Cytoskeleton

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/abrilumab.html

Purity

98.35

Solubility

10 mM in DMSO

Smiles

[Abrilumab]

Molecular Weight

(143.8 kDa)

References & Citations

[1]Iris Dotan, et al. The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti-integrin therapies. Med Res Rev|[2]Christopher A Lamb, et al. Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease. J Crohns Colitis. 2018 Aug 22;12 (suppl_2) :S653-S668.